SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

2/25/22 10:14:06 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $5.00 from $14.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RUBY

Date	Price Target	Rating	Analyst
9/13/2022		Buy → Neutral	Guggenheim
2/25/2022	$14.00 → $5.00	Market Perform	SVB Leerink
11/9/2021	$20.00 → $14.00	Market Perform	SVB Leerink
10/19/2021	$25.00 → $22.00	Equal-Weight	Morgan Stanley